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Abstract
Introduction: Toll-like receptors (TLRs) are an important link between innate and
adaptive immunity. 
Material and methods: Expression of TLR-2, TLR-4, and TLR-9 genes was assessed
in 60 coronary artery disease (CAD) patients and 79 controls by SYBR Green 1
based real time PCR assay. 
Results: Expression of the TLR-2 gene was found to be significantly elevated in
cases (1.295 ±0.09) compared to the controls (1.033 ±0.08) (p = 0.015) whereas
expression of the TLR-9 gene was significantly lower in cases (1.522 ±0.18) than
in the controls (2.165 ±0.16) (p = 0.032). There was no difference in TLR-4
expression levels (p = 0.174). A significant correlation of TLR-2 was observed
with TLR-4 (r = 0.803, p < 0.0001) and TLR-9 (r = 0.264, p = 0.003) as well as
between TLR-4 and TLR-9 (r = 0.303, p = 0.001). A significant association was
seen between TLR 2 (OR 3.94, 95% CI 1.73-8.99, p = 0.001) and TLR-9 (OR 0.297,
95% CI 0.131-0.672, p = 0.004) with CAD after adjustment for age and gender.
Statins did not affect TLR gene expression.
Conclusions: The TLR-2, TLR-4 and TLR-9 genes exhibit a differential pattern of
expression between CAD patients and controls in this Asian Indian cohort. This
observation warrants further investigation, keeping in mind the infectious and
inflammatory elements in perspective, in order to understand the true
implications of TLR in the aetiopathology of CAD and consequent therapeutic
implications. 
Key words: Toll-like receptors, gene expression, coronary artery disease, Asian
Indians.
Introduction 
Atherosclerosis is considered to be an immunomodulatory disease,
wherein infections by common pathogens and the ensuing inflammatory
and immune response mechanisms play a significant role in the regulation
of disease progression [1, 2]. Toll-like receptors (TLRs) are a family of pattern
recognition receptors that serve as the first line of defence against invading
microbes and/or tissue injury [3]. Endothelial cells, macrophages,
adventitious fibroblasts and dendritic cells express TLRs in the
atherosclerotic vessel wall. Twelve different families of TLRs have been
discovered to date, of which TLR-1, TLR-2, TLR-4 and TLR-9 are key receptors
implicated in the development and progression of coronary artery disease
(CAD) [4, 5]. The TLRs recognize a variety of bacterial and fungal
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components that serve as their ligands –
peptidoglycans for TLR-2, lipopolysaccharides for
TLR-4, flagellin for TLR-5 and unmethylated CpG
motifs present in bacterial DNA for TLR-9 [6]. The
TLRs initiate a cross talk between innate and
adaptive immunity [7], resulting in activation of the
nuclear factor-κB (NFκB) mediated inflammatory
response via the direct regulation of immune
responsive genes [8]. The TLR-mediated inflam  -
mation thus acts as an important pathogenic link
between innate immunity and CAD [9]. 
Gene expression studies on the TLR family have
shown that TLR-1, TLR-2 and TLR-4 genes are
particularly elevated in human atherosclerotic
lesions accompanied by parallel activation of TLR-
expressing cells, as shown by the nuclear
translocation of NFκB [10]. Recent findings have
linked the TLR-mediated signalling cascade to
established pathological determinants of plaque
development and destabilization [11, 12]. Direct in
vivo evidence on the pattern of TLR signalling in
LDL receptor and apoE knock-out mice has shown
that regulation of TLR expression is critical for
maintaining immunological homeostasis [13]. TLRs
have sparked great interest in recent times due to
their potential for therapeutic manipulation of the
innate immune system by way of alternate
activation and down-regulation. TLRs can either
serve as adjuvants for an immune-based vaccine
by the induction of atheroprotective immunity [14]
or as antagonists to TLR ligands, thereby arresting
disease progression [15-17]. 
The present investigation is a part of the Indian
Atherosclerosis Research Study (IARS), a large
genetic epidemiological study on Asian Indians,
where the underpinning objectives are to identify
a potential vaccine to fight heart disease and to
identify a strategic ‘high risk’ population for testing
the vaccine. Given the key ability of TLRs to
participate both in atheroprotective and pro-
atherogenic immune responses, the objective of the
present study was to assess the role of TLR in
a cohort selected from the IARS by studying the
expression levels of TLR-2, TLR-4 and TLR-9 as
a pilot exploratory study.  
Material and methods
All participants included in the study were
selected from the IARS, an ongoing study, initiated
and conducted by the Thrombosis Research
Institute (TRI), India, to elucidate the involvement
of genetic and non-genetic factors contributing to
the aetiopathology of CAD among Asian Indians.
The IARS participants were enrolled, based on
predefined inclusion/exclusion criteria, from cardiac
specialty hospitals in Bangalore and Mumbai
situated in the southern and western regions of
India. The CAD patients (n = 60) were selected from
among the IARS probands who had a strong family
history of CVD and age at onset of CAD ≤ 60 years
for men and ≤ 65 years for women. All patients had
angiographically confirmed presence of CAD.
Patients having a history of primary myocardial
disease or congenital heart disease were excluded
from the study. The asymptomatic controls (n = 79)
were matched for age and gender from among
volunteers from the general population. The
controls were considered healthy based on their
ECG result and did not have a personal or family
history of CAD. Individuals were considered to be
diabetic or hypertensive based on self report of
prescription medication. None of the patients were
on insulin treatment. Individuals with concomitant
infection were not enrolled in the study. Parti  -
cipation was by informed voluntary written consent.
The IARS protocol was approved by the institutional
ethics committee and is based on the Indian
Council of Medical Research (ICMR) guidelines on
Bioethics and the Helsinki Declaration for
conducting research on human subjects [18].
RNA isolation
Around 22 ml of blood sample was collected from
all study participants. The serum, EDTA plasma and
citrate plasma were separated into aliquots and
preserved for biomarker assays while the blood pellet
was used for DNA extraction. Around 3 ml of EDTA
whole blood was used for gene expression studies.
Total RNA was extracted from fresh whole blood using
the QIAamp Blood Mini Kit (Qiagen Inc., Valencia, CA,
USA) for RNA extraction as per the recommended
protocol. Purified RNA was converted to cDNA using
the cDNA archive kit (Applied Biosystems Inc., Foster
Coty, CA, USA) and stored at –80°C. 
TLR assays and data analysis
SYBR Green I based cDNA specific real time PCR
assays for TLR-2, TLR-4, TLR-9 and GAPDH genes
were designed and developed in house. Table I
shows the forward and reverse primers as well as
the PCR conditions used for the SYBR green assay.
Expression analysis of TLR-2, TLR-4 and TLR-9 genes
was performed with replicates of the cDNA, using
the GAPDH gene as an endogenous control. Relative
quantitation of gene expression was performed by
a method described previously [19]. The intra-assay
coefficient of variation (CV) of the relative quantities
obtained for TLR-2, TLR-4 and TLR-9 was 5.9%, 6.4%
and 7.6%, respectively, while the inter-assay CV for
the same was estimated to be 7.3%, 9.4% and 8.1%,
respectively. 
Statistical analysis
Multivariate analysis of fold changes in relative
gene expression was performed with and withoutArch Med Sci 5, October / 2011 783
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adjustment for traditional risk factors, namely, age,
gender, history of smoking, hypertension and
diabetes. The correlation amongst the expression
levels of TLR-2,  TLR-4 and  TLR-9 genes was
assessed by multivariate statistics and Pearson’s
correlation test. Logistic regression analysis was
performed to assess the association of TLRs with
CAD after eliminating the effect of age and gender.
SPSS version 15 was employed for statistical
analysis and a nominal p value of 0.05 or less was
considered as statistically significant. 
Results
The clinical characteristics of the study
participants are provided in Table II. There was no
significant difference between cases and controls
with respect to the mean age, gender, systolic and
diastolic blood pressure, body mass index, waist-
hip-ratio, and smoking. Frequency of diabetes and
hypertension was, however, significantly higher in
the cases than in the controls (p < 0.001). Of the 60
CAD patients, 21 of them had suffered a myocardial
infarction (MI) event, while 30 subjects had stable
angina disease. Clinical details were missing for 
9 individuals who had proven CAD based on
a cardiologist’s diagnosis. The mean age at onset
of CAD was 50 ±7.4 years for males and 56.7 ±4.2
years for females.
Gene expression analysis
The expression levels of the TLR-2 gene was
found to be significantly elevated in the cases (1.295
±0.09) as compared to the controls (1.033 ±0.08) 
(p = 0.015). On the other hand, the expression levels
for the TLR-9 gene was significantly lower in the
cases (1.522 ±0.18) than the controls (2.165 ±0.16)
(p = 0.032) while there was no significant
differences in the expression levels for the TLR-4
gene (p = 0.174) (Figure 1). This pattern did not
change following covariate adjustment for age,
gender, history of smoking, hypertension or
diabetes (Figure 2). 
We observed a significant correlation of TLR-2
with TLR-4 (r = 0.803, p < 0.0001) and TLR-9
(r = 0.264, p = 0.003) as well as between TLR-4 and
TLR-9 (r = 0.303, p = 0.001), respectively, after
Genes Primers Sequence PCR condition
TLR2 1642F CCAGGCTCTGGTGCTGACAT Initial denaturation –  95°C for 10', 
1713R AGACTGCCCAGGGAAGAAAAA 40 cycles of denaturation at 95°C for 15 s, 
TLR4 1951F GGCATGCCTGTGCTGAGTT
annealing/extension at 60°C for 1', 
2020R TGAGGACCGACACACCAATGA
final dissociation step 
TLR9 1533F AGTCAATGGCTCCCAGTTCCT
1626R CGTGAATGAGTGCTCGTGGTA
GAPDH2 3210F CAAGGCTGTGGGCAAGGT
3268R GGAAGGCCATGCCAGTGA
Table I. Primer sequences used for TLR genes and GAPDH2 with PCR conditions
Parameter Cases (n = 60) Controls (n = 79) Value of p
Age [years] 52.19 ±7.39 51.76 ±8.27 0.935
Gender (M/F) 53/7 72/7 0.586
Body mass index [kg/m2] 25.6 ±0.49 24.97 ±0.48 0.369
Waist/hip ratio 0.97 ±0.01 0.96 ±0.01 0.302
Systolic blood pressure [mmHg] 121.34 ±1.77 127.03 ±2.21 0.06
Diastolic blood pressure [mmHg] 77.93 ±1.12 81.0 ±1.17 0.069
Height [cm] 166.12 ±1.11 165.52 ±0.83 0.66
Weight [kg] 70.44 ±1.2 68.28 ±1.4 0.265
Diabetes [%] 27 (47.4) 5 (6.4) < 0.0001
Hypertension [%] 31 (55.4) 6 (7.7) < 0.0001
Statin [%] 30 (50.0) 0 –
Smoking (ever) 27 (46.6) 31 (39.7) 0.427
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adjusting for age, gender, diabetes, hypertension
and smoking. There was a significant association
of TLR-2 (OR 3.94, 95% CI 1.73-8.99, p = 0.001) and
TLR-9 (OR 0.297, 95% CI 0.131-0.672, p = 0.004) with
CAD, after adjustment for age and gender. The
predictive probability of the TLRs to accurately
classify the CAD cases and controls based on the
ROC analysis (AUC value) was 0.69 (p < 0.000)
(Figure 3) with overall classification of 62.6% of the
cohort. 
A comparison of the TLR gene expression profile
between the study participants on statin therapy
and those who were not on the lipid-lowering drug
revealed that there was no significant difference in
the relative expression profile for all the three TLR
genes (Figure 3).
Discussion
Given the high global prevalence of CVD and its
co-morbidities, there is an urgent need to identify
novel ways of predicting and managing cardio  -
vascular risk. It is common knowledge that
conventional risk factors account for only 50% of
the disease prevalence and existing modalities for
addressing this risk are primarily through life style
interventions and/or through use of the limited
choice of medications available in the market today.
Based on the clinico-epidemiological and experi  -
mental studies, there is a growing understanding
that infection may play a significant role in the
initiation and progression of atherosclerotic disease
[20-22]. Therefore, novel therapies such as
modulation of the immune system have opened up
unique  opportunities to redress the growing
concern of CVD burden. In this connection, the TLRs
play a critical role in bridging the gap between
immune response and cardiovascular disease
progression. Lessons learnt from knock out mouse
models (apoE –/–, double knock outs such as 
apoE –/– and TLR-4 –/– or apoE –/– and CD14 –/–)
have provided strong mechanistic evidence that
TLRs are responsible for the exacerbation of
atherosclerotic disease [23]. Mechanisms of TLR
action are manifold – ability to directly interfere with
cholesterol metabolism in the macrophages by
serving as a ligand for minimally modified LDL,
a proathe  rogenic and proinflam  matory lipoprotein
[24], interaction on the endothelial cell surface
resulting in the enhanced secretion of IL-18,
a potent proinflammatory cytokine [25], and cross
reaction between bacterial and human heat shock
protein 60 (HSP60) through molecular mimicry.
The signalling here is mediated through TLR-2
and/or TLR-4, leading to the activation of NFκB
dependent proinflammatory gene targets [26-28]
and consequent accumulation of lipids and
leukocytes in the atheroma [3]. Pathological
changes that occur during the atherosclerotic
disease process release endogenous inflammatory
molecules and oxida  tively modified lipids that serve
as ligands that engage the TLRs and activate their
expression [29].
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Figure 1. Relative gene expression in TLR-2, TLR-4 and
TLR-9 between cases and controls before adjusting
for conventional risk factors
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Figure 2. Relative gene expression in TLR-2, TLR-4
and TLR-9 between cases and controls after
adjusting for age, gender, hypertension, diabetes and
smoking
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Figure 3. Effect of statin usage on fold changes in
TLR gene expression in CAD patients
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The Bruneck study provided the first epide  -
miological evidence that circulating pro-inflam  -
matory mediators such as bacterial lipopolysac  -
charides (LPS) can constitute a strong risk factor
for atherosclerosis development [30]. Subsequently,
TLR-1, TLR-2 and TLR-4 were shown to be markedly
elevated in human atherosclerotic plaque
specimens [10] and in the medium and large arterial
trees [31]. 
The above studies highlight the prominent role
of TLRs as an emerging biomarker of atherosclerosis
and a potential therapeutic target against CAD.
Given this topical interest in TLRs, the present study
was an exploratory study to understand the role of
circulating TLR expression in CAD patients with
strong familial predisposition to CAD. Our initial
findings reveal that there is a differential pattern
of gene expression in CAD patients as compared to
the controls. In our study, the expression of TLR-2,
was found to be significantly elevated while TLR-9
was lower in CAD patients as compared to controls.
On the other hand, there was no difference in the
levels of TLR-4 expression between the two groups.
High levels of TLR-2 expression were reported on
the surface of circulating monocytes, independent
of established risk factors [32]. Genetic variations
in the TLRs can attenuate (Asp299Gly in TLR-4) [33]
or enhance the inflammatory and immune response
to pathogenic challenge and thereby influence the
pathogenesis or outcome of disease [34, 35]. Novel
mutations have been identified in TLR-1 (Ser150Gly
and Val220Met) and TLR-2 (Phe670Leu) that alter
the ability of TLRs to recognize specific PAMPs
associated with infection by Mycobacterium
avium subsp. paratuberculosis (MAP) [36].  
In the IARS, we have measured the antibody
titres to various common pathogens such as
Cytomegalovirus, Chlamydia pneumoniae, Helico -
bacter pylori and Herpes simplex virus 1. Sero  -
positivity to the first three pathogens was found to
be significantly higher in CAD patients (p < 0.05) as
compared to their unaffected family members; also,
the number of CAD patients was higher in the
group with multiple rather than single infections
(data unpublished), supporting the hypothesis that
total pathogen burden rather than single infections
are an important aetiopathological factor for CAD
[37, 38]. Given this background knowledge, it is not
surprising that we observed enhanced expression
for TLR-2 in our patients selected from the IARS
cohort. However, these preliminary findings have
to be extended to a larger cohort to understand
the true implications of the fold changes amongst
the various TLRs and their downstream modulation
of proinflammatory cytokines. In a recent report on
the analysis of vessel-specific profiling of various
TLRs in the medium and large arteries, it has been
shown that while TLR-2 and TLR-4 are ubiquitously
expressed, TLR-7 and TLR-9 may be infrequent and
the other TLRs may show selective expression [31].
This again has to be further validated in the present
context. In a recent study, a decrease in the
expression of TLR-4 was shown to be associated
with progression of cervical neoplasia in cases of
infections with human papillomavirus (HPV) [39].
Yet another interesting study on Sprague-Dawley
rats has shown that the underlying mechanism of
ischemic preconditioning during repeated ischemic
reperfusion might be related to decreased levels of
TLR-4 expression and reduced levels of proin  -
flammatory cytokines, TNF-α  and IL-1β  [40]. 
TLR signalling has been shown to increase
plaque vulnerability through myeloid differentiation
primary response gene 88 (MyD88), a signalling
adaptor shared by most TLR genes [17, 40]. In our
study over 41% of CAD patients had experienced
an MI event, suggesting the possible association of
enhanced TLR expression with adverse cardio  -
vascular outcome.
Statin treatment, primarily advocated for
lowering of cholesterol levels, has been shown to
decrease TLR-4 signalling through attenuation of
the LPS responsiveness [41]. In contrast, such
signalling has also been shown to enhance TLR-
mediated cytokine expression in astrocytes through
negative feedback regulation of the Rho proteins
[42]. However, in the present study, statins did not
appear to influence the pattern of TLR expression
in CAD patients.
Although our pilot study reveals alterations in
expression levels of TLR-2 and TLR-9 genes in the
present study, there are certain limitations such as
the small sample size, increased prevalence of co-
morbidities such as diabetes and hypertension and
use of statins in the patient group as compared to
the controls. These are being addressed in a further
study involving well-matched control groups.
Furthermore, we need to evaluate the influence of
altered TLR expression on downstream cytokines
that might provide stronger evidence on the mode
of TLR regulation in atherosclerosis. An interesting
association has been reported on the enhanced
expression of IL-10-dependent elevated expression
of TLR-9 by Treg cells through induction by CD3+
T cells in the presence of vitamin D, which has
significant implications for vaccine design [43].
Developing a vaccine against atherosclerosis is one
of our primary objectives, and the report by Urry 
et al. provides critical insights into mechanism of
TLR regulation and the balance achieved by the
T regulatory (Treg) cells in coordinating an effective
immune response. We have observed that over 97%
of the CAD patients have chronic vitamin D defi  -
ciency in a pilot study in the IARS (Insert reference
# 44 – PMID: 216110492). The reported association
of vitamin D mediated immune response of TLRs
opens up exciting avenues for detailed inve  s  -
tigations.  786 Arch Med Sci 5, October / 2011
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In conclusion, the present study provides early
leads on the differential pattern in the expression
levels of TLR-2, TLR-4 and TLR-9 genes in CAD
patients with strong familial predisposition to CVD.
This is in line with the emerging paradigm that
atherosclerosis is a pathogen-mediated immuno  -
modulatory disease. Further work is required to
understand the true profile of TLRs, their correlation
with presence of infection and other inflammatory
biomarkers, as well as their functional relevance to
the pathology of coronary artery disease in Asian
Indians.
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